Maximum Somatic Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden Predicts the Efficacy of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Article Oncology

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok et al.

Summary: The 6.5-year results of the CheckMate 067 trial demonstrate durable clinical benefits with nivolumab plus ipilimumab or nivolumab monotherapy compared to ipilimumab alone in patients with advanced melanoma.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors

Wei Nie et al.

Summary: The study suggests that ctDNA-adjusted bTMB might predict overall survival benefit in NSCLC patients receiving ICIs, with no significant association with tumor burden noted.

BMC MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Edward S. Kim et al.

Summary: In patients with non-small cell lung cancer, blood TMB shows potential as a predictive biomarker for first-line atezolizumab monotherapy, with higher ORR in the high bTMB group. However, the results for PFS were not statistically significant. Additionally, at 36.5-month follow-up, bTMB >= 16 was associated with longer OS compared to bTMB < 16.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study

Han Si et al.

Summary: This study validated a new algorithm for measuring tumor mutational burden (bTMB) from blood and demonstrated its clinical utility in the MYSTIC trial. High bTMB, determined using the algorithm with a cutoff of >= 20 mut/Mb, was predictive of clinical benefit with durvalumab+tremelimumab versus chemotherapy.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Correction Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)

Borghaei

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Letter Biochemistry & Molecular Biology

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer

Wenfeng Fang et al.

MOLECULAR CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

Stefan C. Dentro et al.

Summary: By extensively characterizing intra-tumor heterogeneity (ITH) across 2,658 cancer samples spanning 38 cancer types, this study found evidence of distinct subclonal expansions in nearly all informative samples, with frequent branching relationships between subclones. Positive selection of subclonal driver mutations was observed across most cancer types, indicating the importance of ITH and its drivers in tumor evolution.

CELL (2021)

添加到收藏夹

Article Oncology

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer

Hossein Borghaei et al.

Summary: Immunotherapy with nivolumab has shown improved overall survival and safety compared to docetaxel in patients with advanced NSCLC in two phase III trials. Pooled 5-year data demonstrated a significant survival benefit with nivolumab and no new safety concerns.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology